BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 15051038)

  • 1. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2003 Oct; 10(7):443-6. PubMed ID: 14519487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
    Atkins KA; Arronte N; Darus CJ; Rice LW
    Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
    Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
    J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
    Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
    Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
    Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
    Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
    Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E
    J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium.
    Bogusiewicz M; Stryjecka-Zimmer M; Postawski K; Jakimiuk AJ; Rechberger T
    Gynecol Endocrinol; 2007 Sep; 23(9):541-6. PubMed ID: 17943549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-1 and -9 promoter polymorphisms are not associated with an increased risk of uterine leiomyomas in a Japanese population.
    Takemura N; Yoshida S; Kennedy S; Deguchi M; Ohara N; Maruo T
    J Soc Gynecol Investig; 2006 Apr; 13(3):232-6. PubMed ID: 16638593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.